Overview

Message from Leadership

The 2018 fiscal year begins GHIT’s second five-year phase of operations after our successful replenishment in 2017. We are pleased to report on our progress and performance, made possible by our partner’s unwavering efforts and commitment toward developing game-changing innovations for global health. We are thrilled to be closer than ever to graduating innovative clinical candidates from our portfolio and putting them into the hands of those who need them most.

Since its 2013 establishment, GHIT has catalyzed the research and development (R&D) of new global health innovations for neglected patients by facilitating cross-sector partnerships between Japanese and non-Japanese entities. GHIT has invested USD 170M in 80 projects to date; currently, 22 discovery projects, 14 preclinical projects, and 8 clinical trials are under way in low-and middle-income countries (LMICs). Our most advanced clinical candidates include a urine-based rapid tuberculosis (TB) diagnostic kit, a pediatric formulation of the gold-standard drug for schistosomiasis, and a long-lasting mycetoma drug. It is consistently clear to us that our development partners and co-investors share our mission, passion, and sense of urgency to progress. We are committed to the registration of two products from our portfolio by 2022.

Because we recognize that innovation is valueless without access, we also remain committed to the integration of access at every step of the R&D process. In keeping with this core piece of our institutional DNA, this past year we co-launched—together with the Government of Japan and the Access Delivery Partnership led and coordinated by the United Nations Development Programme (UNDP) —“Uniting Efforts for Innovation, Access and Delivery,” a platform for dialogue and collaboration among key stakeholders involved in innovation, access, and delivery of health technologies for unmet health needs in LMICs.

All of these achievements build important momentum for the year ahead. In 2019, Japan will host its first G20 Summit, including the first-ever meeting between health and finance ministers, as well as the Tokyo International Conference on African Development VII. Both convenings represent critical milestones for Japan’s and GHIT’s leadership in global health and significant opportunities to further strengthen and expand R&D and access partnerships. The UN High-Level Meeting on Universal Health Coverage (UHC) in September 2019 also provides a critical opportunity for Japan to show its leadership in this area and increase momentum toward attaining UHC across the globe.

We are so grateful for the skill, passion, and steadfast commitment that every single one of our governors, funding partners, and development/access partners actively brings to the table every day. They motivate us to reach higher, work better, and keep pushing toward our vision.

Hiroki Nakatani, MD, PhD, MHPEdBoard Chair

Catherine K. Ohura, MS, PMPChief Executive Officer